Stockscreener 앱 받기
3.76
9.30%
0.32
시간 외 거래:
3.77
0.01
+0.27%
전일 마감가:
$3.44
열려 있는:
$3.4
하루 거래량:
292.77K
Relative Volume:
2.61
시가총액:
$120.95M
수익:
$4.06M
순이익/손실:
$-50.22M
주가수익비율:
-2.3231
EPS:
-1.6185
순현금흐름:
$-25.37M
1주 성능:
-8.52%
1개월 성능:
-23.89%
6개월 성능:
+12.57%
1년 성능:
+0.00%
1일 변동 폭
$3.263
$3.79
1주일 범위
$2.42
$4.37
52주 변동 폭
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
명칭
Insight Molecular Diagnostics Inc
전화
949-409-7600
주소
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.76 | 120.95M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 개시 | Lake Street | Buy |
| 2022-05-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-03-17 | 재개 | Needham | Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 개시 | BTIG Research | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Speculative Buy |
| 2020-07-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 개시 | Needham | Buy |
| 2019-02-13 | 개시 | Piper Jaffray | Overweight |
| 2019-01-29 | 업그레이드 | Janney | Neutral → Buy |
| 2018-12-19 | 재개 | Lake Street | Buy |
모두보기
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
Stock List: Research Stocks from Around the World - GuruFocus
BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada
BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com
Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
IMDX CFO’s RSUs Vest as Company Withholds Shares for Taxes - Stock Titan
IMDX (IMDX) VP Yang sees RSUs vest while shares withheld for taxes - Stock Titan
CEO at Insight Molecular (IMDX) vests 47,170 RSUs with no share sale - Stock Titan
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Trade Insight Molecular Diagnostics IncOCX CFD - Capital.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst - Yahoo! Finance Canada
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham reiterates Buy on Insight Molecular stock, $9 target By Investing.com - Investing.com India
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Needham reiterates Buy on Insight Molecular stock, $9 target - Investing.com
Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx - MSN
Earnings call transcript: Insight Molecular Diagnostics Q4 2025 reveals strategic milestones - Investing.com India
Insight Molecular Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission - ChartMill
Insight Molecular Diagnostics: Q4 Earnings Snapshot - crossville-chronicle.com
IMDX: Revenue doubled and net loss narrowed as focus shifted to transplant diagnostics and kit commercialization - TradingView
IMDX: FDA submission of GraftAssureDx and strong clinical data set stage for 2026 commercialization - TradingView
Insight Molecular 2025 10-K: Revenue $4.06M, Net Loss $50.22M - TradingView
Insight Molecular Diagnostics posts Q4 2025 results; revenue $1.1M in quarter, $4.1M full year - TradingView
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Insight Molecular Diagnostics (IMDX) files GraftAssureDx with FDA and reports 2025 loss - Stock Titan
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results - taiwannews.com.tw
IMDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Molecular Diagnostics Market Is Going to BoomKey Factors Driving Unstoppable Growth - openPR.com
IMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - marketscreener.com
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - The Manila Times
Oncocyte : to Begin Trading on the Nasdaq Stock Market on March 8, 2021 - marketscreener.com
HTGMQ (HTG Molecular Diagnostics) PNK at $0.0001 19 Mar 2026: top gainer insight - Meyka
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR) - The Globe and Mail
IMDXInsight Molecular Diagnostics Inc. Latest Stock News & Market Updates - Stock Titan
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones - Yahoo Finance
Certain Restricted Stock Units of Insight Molecular Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026. - marketscreener.com
Certain Warrants of Insight Molecular Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026. - marketscreener.com
Insight Molecular Diagnostics (IMDX) Advances with GraftAssure T - GuruFocus
Insight Molecular Diagnostics Inc Highlights New Peer-Reviewed Study Demonstrating GraftAssure Assay Technology Superiority - marketscreener.com
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score - The Manila Times
Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score - Bitget
Insight Molecular Diagnostics Nears FDA Submission for Kidney Transplant Rejection Test Kit - Clinical Lab Products
Insight Molecular Diagnostics Nears FDA Submission with GraftAssureDx Milestones - Zenopa
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - Bitget
Insight Molecular Diagnostics completes key milestones advancing Graftassuredx toward FDA submission - marketscreener.com
Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission - TradingView
Kidney transplant test GraftAssureDx nears FDA submission in $2B market - Stock Titan
Insight Molecular Diagnostics Inc (IMDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Insight Molecular Diagnostics Inc 주식 (IMDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| James Andrea S. | Chief Financial Officer |
Oct 31 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
201,231 |
0.17%
1.11%
자본화:
|
볼륨(24시간):